Exact Mass: 273.0867
Exact Mass Matches: 273.0867
Found 71 metabolites which its exact mass value is equals to given mass value 273.0867,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Modafinil
Modafinil is a stimulant drug marketed as a wakefulness promoting agent and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(2,5-Dioxopyrrolidin-1-yl) 5-(2-hydroxyethoxy)-4-oxopentanoate
5-Hydroxymethylcytidine
5-(Hydroxymethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
provigil
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-amino-3-(1,3-benzodioxol-5-yl)-2,2-dimethylpropanoic acid,hydrochloride
1-(3-FLUOROBENZYL)-4-PIPERIDINECARBOXYLICACIDHYDROCHLORIDE
5-Nitro-2-(3-piperidinylmethoxy)pyridinehydrochloride
Methoxypolyethylene glycol succinate N-hydroxysuccinimide
3-(4-Fluorophenyl)-5-(furan-2-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide
3-(2-PHENYL-IMIDAZOL-1-YL)-PROPYLAMINE DIHYDROCHLORIDE
5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,hydrochloride
(S)-(-)- 6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3- CARBOXYLIC ACID HYDROCHLORIDE
1-(4-FLUORO-BENZYL)-PIPERIDINE-3-CARBOXYLIC ACID HYDROCHLORIDE
2-Pyridin-4-yl-benzo[h]chromen-4-one
D004791 - Enzyme Inhibitors > D001571 - Benzoflavones
Ethyl morpholine-2-carboxylate 2,2,2-trifluoroacetate
(3-(N-isopropylsulfamoyl)-4-Methoxyphenyl)boronic acid
Methyl 2-amino-5-(3-chloropropoxy)-4-methoxybenzoate
2-(2-Chlorophenyl)-1-[4-(dimethylamino)phenyl]ethanone
2-(Benzofuran-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione,2-Benzofuranboronic acid MIDA ester
armodafinil
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D064690 - Wakefulness-Promoting Agents D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
6-[N-(2-chloropyrimidin-4-yl)amino]-2,3-dimethyl-2H-indazole
4-METHYL-N-(4-METHYL-BENZYLIDENE)BENZENESULFONAMIDE
(S)-6,7 DIMETHOXY 1,2,3,4 TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLOIC ACID HYDROCHLORIDE
(2-{[1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]methoxy}ethyl)amine hydrochloride
1-(4-METHOXY-2-NITROPHENYL)PIPERAZINE HYDROCHLORIDE
1-(1-methylpyrazol-4-yl)sulfonylpiperidine-4-carboxylic acid
N-(2-aminopyrimidin-5-yl)-2-methyl-5-nitrobenzamide
4,7-Methano-1H-(1,2)diazeto(3,4-f)benzotriazole, 1-(4-chlorophenyl)-3a,4,4a,6a,7,7a-hexahydro-
4-(5-Methoxy-1,2-dimethyl-1h-indol-3-yl)thiazol-2-ylamine
N-[4-(2-pyridinyl)-2-thiazolyl]cyclopentanecarboxamide
2-[4-(aminomethyl)phenyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one
1-(4-Methoxyphenyl)-3-(6-methyl-2-pyridinyl)thiourea
2-methyl-N-[(E)-(2-nitrophenyl)methylideneamino]pyrazole-3-carboxamide
N-(5-fluoro-2-methylphenyl)-1,3-benzodioxole-5-carboxamide
3-(1,3-Benzoxazol-2-ylsulanyl)-5,5-dimethylcyclohex-2-en-1-one
SIB-1553A
SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders[1][2].
